Strategies for stalling malignancy: Targeting cancer's addiction to Hsp90

Current Topics in Medicinal Chemistry

Volumn 9, Issue 15, 2009, Pages 1352-1368

  Prodromou, Chrisostomos ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Co chaperones; Drug design; Heat shock protein; Hsp90

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; CELL CYCLE PROTEIN 37; HEAT SHOCK PROTEIN 90;

ANTINEOPLASTIC ACTIVITY; DRUG TARGETING; ENZYME STRUCTURE; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; PROTEIN CONFORMATION;

EID: 74249116634     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789895656     Document Type: Review

References (138)

1. Maloney, A.; Workman, P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2(1), 3-24.
2. Workman, P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206(2), 149-157.
3. Picard, D. Heat-shock protein 90, a chaperone for folding and regulation. Cell. Mol. Life Sci. 2002, 59(10), 1640-1648.
4. Pratt, W.B.; Toft, D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood), 2003, 228(2), 111-133.
5. Scroggins, B.T.; Prince, T.; Shao, J.; Uma, S.; Huang, W.; Guo, Y.; Yun, B. G.; Hedman, K.; Matts, R.L.; Hartson, S.D. High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients. Biochemistry 2003, 42(43), 12550-12561.
6. Pearl, L.H.; Prodromou, C. Structure, function and mechanism of the Hsp90 molecular chaperone. Adv. Protein Chem. 2002, 59, 157-185.
7. Pearl, L.H.; Prodromou, C; Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 2008, 410(3), 439-453.
8. Pacey, S.; Banerji, U.; Judson, I.; Workman, P. Hsp90 inhibitors in the clinic. Handb. Exp. Pharmacol. 2006, (172), 331-358.
9. Solit, D.B.; Osman, I.; Polsky, D.; Panageas, K.S.; Daud, A.; Goydos, J.S.; Teitcher, J.; Wolchok, J.D.; Germino, F.J.; Krown, S.E.; Coit, D.; Rosen, N.; Chapman, P.B. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14(24), 8302-8307.
10. Solit, D.B.; Ivy, S.P.; Kopil, C.; Sikorski, R.; Morris, M.J.; Slovin, S.F.; Kelly, W.K., DeLaCruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M.J.; Rosen, N. and Scher, H.I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 2007, 13(6), 1775-1782.
11. Jensen, M.R.; Schoepfer, J.; Radimerski, T.; Massey, A.; Guy, C.T.; Brueggen, J.; Quadt, C.; Buckler, A.; Cozens, R.; Drysdale, M.J.; Garcia-Echeverria, C.; Chene, P. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 2008, 10(2), R33.
12. Heath, E.I.; Gaskins, M.; Pitot, H.C.; Pili, R.; Tan, W.; Marschke, R.; Liu, G.; Hillman, D.; Sarkar, F.; Sheng, S.; Erlichman, C; Ivy, P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Prostate Cancer 2005, 4(2), 138-141.
13. Ronnen, E.A.; Kondagunta, G.V.; Ishill, N.; Sweeney, S.M.; Deluca, J.K.; Schwartz, L.; Bacik, J; Motzer, R.J. A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest. New Drugs 2006, 24(6), 543-546.
14. Chiosis, G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6(11), 1183-1191.
15. Chiosis, G.; Rodina, A; Moulick, K. Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer Agents Med. Chem. 2006, 6(1), 1-8.
16. Chiosis, G; Tao, H.; Purine-scaffold Hsp90 inhibitors. IDrugs 2006, 9(11), 778-782.
17. Brough, P.A., Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J.E.; Cheung, K.M.; Collins, I.; Davies, N.G.; Drysdale, M.J.; Dymock, B.; Eccles, S.A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R.E.; James, K.; Jordan, A.M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T.P.; McDonald, E.; Northfield, C.J.; Pearl, L.H., Prodromou, C.; Ray, S.; Raynaud, F.I.; Roughley, S.D.; Sharp, S.Y.; Surgenor, A.; Walmsley, D.L.; Webb, P.; Wood, M.; Workman, P; Wright, L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51(2), 196-218.
18. Eccles, S.A.; Massey, A.; Raynaud, F.I.; Sharp, S.Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven Brandon, A.; Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T.P.; Cheung, K.M.; Kalusa, A.; Jones, K.; McDonald, E.; Barril, X.; Brough, P.A.; Cansfield, J.E.; Dymock, B.; Drysdale, M.J.; Finch, H.; Howes, R.; Hubbard, R.E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68(8), 2850-2860.
19. Lundgren, K.; Zhang, H.; Brekken, J.; Huser, N.; Powell, R.E.; Timple, N.; Busch, D.J.; Neely, L.; Sensintaffar, J.L.; Yang, Y.C.; McKenzie, A.; Friedman, J.; Scannevin, R.; Kamal, A.; Hong, K.; Kasibhatla, S.R.; Boehm, M.F. and Burrows, F.J BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol. Cancer Ther. 2009, 8(4), 921-929.
20. Mimnaugh, E.G.; Chavany, C.; Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 1996, 271(37), 22796-22801.
21. Siligardi, G; Hu, B.; Panaretou, B.; Piper, P.W.; Pearl, L.H.; Prodromou, C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J. Biol. Chem. 2004, 279(50), 51989-51998.
22. Prodromou, C; Roe, S.M.; Piper, P.W.; Pearl, L.H. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nature Struct. Biol. 1997, 4(6), 477-482.
23. Stebbins, C.E.; Russo, A.A.; Schneider, C.; Rosen, N.; Hartl, F.U.; Pavletich, N. P.; Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89(2), 239-250.
24. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Panaretou, B.; Piper, W.P.; Pearl, L.H. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell 2003, 11(3), 647-658.
25. Harris, S.F.; Shiau, A.K.; Agard, D.A. The crystal structure of the carboxy-terminal dimerization domain of htpG, the Escherichia coli Hsp90, reveals a potential substrate binding site. Structure 2004, 12(6), 1087-1097.
26. Soldano, K.L.; Jivan, A.; Nicchitta, C.V.; Gewirth, D.T. Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation, J. Biol. Chem. 2003, 278(48), 48330-48338.
27. Huai, Q; Wang, H.; Liu, Y.; Kim, H.Y.; Toft, D.; Ke, H. Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure 2005, 13(4), 579-590.
28. Dollins, D.E.; Immormino, R.M.; Gewirth, D.T. Structure of unliganded GRP94, the endoplasmic reticulum Hsp90. Basis for nucleotide-induced conformational change. J. Biol. Chem. 2005, 280(34), 30438-30447.
29. Dollins, D.E.; Warren, J.J.; Immormino, R.M.; Gewirth, D.T. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell, 2007, 28(1), 41-56.
30. Meyer, P.; Prodromou, C.; Liao, C.; Hu, B.; Roe, S.M; Vaughan, C.K.; Vlasic, I.; Panaretou, B.; Piper, P.W.; Pearl, L.H. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 2004, 23(3), 511-519.
31. Prodromou, C; Panaretou, B; Chohan, S.; Siligardi, G.; O'Brien, R.; Ladbury, J.E.; Roe, S.M.; Piper, P.W.; Pearl, L.H. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J. 2000, 19(16), 4383-4392.
32. Roe, S.M.; Prodromou, C.; O.Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. The Structural Basis for Inhibition of the Hsp90 Molecular Chaperone, by the Anti-tumour Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42(2), 260-266.
33. Li, Y.; Zhang, T.; Schwartz, S.J.; Sun, D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist. Update 2009, 12(1-2), 17-27.
34. Bohen, S.P.; Yamamoto, K.R. Isolation of Hsp90 mutants by screening for decreased steroid receptor function. Proc. Natl. Acad. Sci. USA 1993, 90(23), 11424-11428.
35. Sato, S.; Fujita, N.; Tsuruo, T. Modulation of akt kinase activity by binding to hsp90. Proc. Natl. Acad. Sci. USA 2000, 97(20), 10832-10837.
36. Nathan, D.F; Lindquist, S. Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase. Mol. Cell Biol. 1995, 15(7), 3917-3925.
37. Vaughan, C.K.; Gohlke, U.; Sobott, F.; Good, V.M.; Ali, M.M.; Prodromou, C.; Robinson, C.V.; Saibil, H.R.; Pearl, L.H. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 2006, 23(5), 697-707.
38. Ali, M.M.; Roe, S.M.; Vaughan, C.K.; Meyer, P.; Panaretou, B.; Piper, P.W.; Prodromou, C.; Pearl, L.H. Crystal structure of an Hsp90-nucleotide-p23/ Sba1 closed chaperone complex. Nature 2006, 440(7087), 1013-1017.
39. Shiau, A.K.; Harris, S.F.; Southworth, D.R.; Agard, D. A. Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006, 127(2), 329-340.
40. Wigley, D.B.; Davies, G.J.; Dodson, E.J.; Maxwell, A.; Dodson, G. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature 1991, 351(6328), 624-629.
41. Ban, C.; Yang, W. Crystal structure and ATPase activity of MutL: Implications for DNA repair and mutagenesis. Cell 1998, 95(4), 541-552.
42. Donze, O.; Picard, D. Hsp90 binds and regulates Gcn2, the ligand-inducible kinase of the alpha subunit of eukaryotic translation initiation factor 2. Mol. Cell. Biol. 1999, 19(12), 8422-8432.
43. Immormino, R.M.; Dollins, D.E.; Shaffer, P.L.; Soldano, K.L.; Walker, M.A.; Gewirth, D.T. Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone. J. Biol. Chem, 2004, 279(44), 46162-46171.
44. Krukenberg, K.A.; Forster, F.; Rice, L.M.; Sali, A.; Agard, D. A. Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90. Structure 2008, 16(5), 755-765.
45. Southworth, D.R.; Agard, D. A. Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. Mol. Cell 2008, 32(5), 631-640.
46. Frey, S.; Leskovar, A.; Reinstein, J.; Buchner, J. The ATPase cycle of the endoplasmic chaperone Grp94. J. Biol. Chem. 2007, 282(49), 35612-35620.
47. Leskovar, A.; Wegele, H.; Werbeck, N.D.; Buchner, J.; Reinstein, J. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J. Biol. Chem. 2008, 283(17), 11677-11688.
48. Panaretou, B.; Prodromou, C.; Roe, S.M.; O'Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 1998, 17(16), 4829-4836.
49. Vaughan, C.K.; Piper, P.W.; Pearl, L.H.; Prodromou, C. A common conformationally coupled ATPase mechanism for yeast and human cytoplasmic HSP90s. FEBS J. 2009, 276(1), 199-209.
50. Neckers, L.; Schulte, T.W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs 1999, 17(4), 361-373.
51. Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S.V. Development of radicicol analogues. Curr. Cancer Drug Targets 2003, 3(5), 359-369.
52. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 2007, 1113, 202-216.
53. Smith, V.; Sausville, EA.; Camalier, R.F.; Fiebig, H.H.; Burger, A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 2005, 56(2), 126-137.
54. Sydor, J.R.; Normant, E.; Pien, C.S.; Porter, J.R.; Ge, J.; Grenier, L.; Pak, R.H.; Ali, J.A.; Dembski, M.S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M.A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D.S.; Wright, J.; Barrett, J.A.; Palombella, V.J.; Adams, J.; Tong, J.K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA. 2006, 103(46), 17408-17413.
55. Tian, Z.Q.; Wang, Z.; MacMillan, K.S.; Zhou, Y.; Carreras, C.W.; Mueller, T.; Myles, D. C.; Liu, Y. Potent cytotoxic C-11 modified geldanamycin analogues. J. Med. Chem. 2009, 52(10), 3265-3273.
56. Donnelly, A.; Blagg, B.S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 2008, 15(26), 2702-2717.
57. Banerji, U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 2009, 15(1), 9-14.
58. Tsutsumi, S.; Beebe, K.; Neckers, L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol. 2009, 5(5), 679-688.
59. Hadden, M.K.; Galam, L.; Gestwicki, J.E.; Matts, R.L.; Blagg, B.S. Derrubone, an inhibitor of the Hsp90 protein folding machinery. J. Nat. Prod. 2007, 70(12), 2014-2018.
60. McDonald, E.; Jones, K.; Brough, P.A.; Drysdale, M.J.; Workman, P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem., 2006, 6(11), 1193-1203.
61. Solit, D.B.; Chiosis, G. Development and application of Hsp90 inhibitors. Drug Discov. Today, 2008, 13(1-2), 38-43.
62. Cheung, K.M.; Matthews, T.P.; James, K.; Rowlands, M.G.; Boxall, K.J.; Sharp, S.Y.; Maloney, A.; Roe, S.M.; Prodromou, C.; Pearl, L.H.; Aherne, G. W.; McDonald, E.; Workman, P. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15(14), 3338-3343.
63. Sharp, S.Y.; Prodromou, C.; Boxall, K.; Powers, M.V.; Holmes, J.L.; Box, G.; Matthews, T.P.; Cheung, K.M.; Kalusa, A.; James, K.; Hayes, A.; Hardcastle, A.; Dymock, B.; Brough, P.A.; Barril, X.; Cansfield, J.E.; Wright, L.; Surgenor, A.; Foloppe, N.; Hubbard, R.E.; Aherne, W.; Pearl, L.H.; Jones, K.; McDonald, E.; Raynaud, F.; Eccles, S.; Drysdale M; Workman, P. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 2007, 6(4), 1198-1211.
64. Orosz, A.; Szabo, A.; Szeman, G.; Janaky, T.; Somlai, C.; Penke, B.; Bodor, A.; Perczel, A. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect. Int. J. Biochem. Cell Biol. 2006, 38(8), 1352-1362.
65. Kaur, J.; Kaur, J.; Ralhan, R. Induction of apoptosis by abrogation of HSP70 expression in human oral cancer cells. Int. J. Cancer 2000, 85(1), 1-5.
66. Wu, C. Heat shock transcription factors: structure and regulation. Annu. Rev. Cell Dev. Biol. 1995, 11, 441-469.
67. Whitesell, L.; Bagatell, R.; Falsey, R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr. Cancer Drug Targets 2003, 3(5), 349-358.
68. Schmitt, E.; Maingret, L.; Puig, P.E.; Rerole, A.L.; Ghiringhelli, F.; Hammann, A.; Solary, E.; Kroemer, G.; Garrido, C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006, 66(8), 4191-4197.
69. McCollum, A.K.; TenEyck, C. J.; Stensgard, B.; Morlan, B.W.; Ballman, K. V.; Jenkins, R.B.; Toft, D.O.; Erlichman, C. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res. 2008, 68(18), 7419-7427.
70. McCollum, A.K.; Lukasiewicz, K.B.; Teneyck, C.J.; Lingle, W.L.; Toft, D.O.; Erlichman, C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol. Cancer Ther. 2008, 7(10), 3256-3264.
71. Marcu, M.G.; Schulte, T.W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90- dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92(3), 242-248.
72. Garnier, C.; Lafitte, D.; Tsvetkov, P.O.; Barbier, P.; Leclerc-Devin, J.; Millot, J.M.; Briand, C.; Makarov, A.A.; Catelli, M.G.; Peyrot, V. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J. Biol. Chem. 2002, 277(14), 12208-12214.
73. Marcu, M.G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L.M. The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone. J. Biol. Chem. 2000, 275(47), 37181-37186.
74. Soti, C.; Racz, A.; Csermely, P. A Nucleotide-dependent molecular switch controls ATP binding at the C- terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem. 2002, 277(9), 7066-7075.
75. Allan, R.K.; Mok, D.; Ward, B.K.; Ratajczak, T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J. Biol. Chem. 2006, 281(11), 7161-7171.
76. McConkey, D.J.; Zhu, K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Update 2008, 11(4-5), 164-179.
77. Burlison, J.A.; Blagg, B.S. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Org. Lett. 2006, 8(21), 4855-4858.
78. Burlison, J.A.; Neckers, L.; Smith, A.B.; Maxwell, A.; Blagg, B.S. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J. Am. Chem. Soc. 2006, 128(48), 15529-15536.
79. Le Bras, G; Radanyi, C.; Peyrat, J.F.; Brion, J.D.; Alami, M.; Marsaud, V.; Stella, B.; Renoir, J.M. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J. Med. Chem. 2007, 50(24), 6189-6200.
80. Palermo, C.M.; Westlake, C.A.; Gasiewicz, T.A. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 2005, 44(13), 5041-5052.
81. Donnelly, A.C.; Mays, J.R.; Burlison, J.A.; Nelson, J.T.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B.S. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J. Org. Chem. 2008, 73(22), 8901-8920.
82. Kelland, L.R.; Sharp, S.Y.; Rogers, P.M.; Myers, T.G.; Workman, P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 1999, 91(22), 1940-1949.
83. Prodromou, C.; Nuttall, J.M.; Millson, S.H.; Roe, S.M.; Sim, T.S.; Tan, D.; Workman, P.; Pearl, L.H.; Piper, P.W. Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem. Biol. 2009, 4(4), 289-297.
84. Panaretou, B.; Siligardi, G.; Meyer, P.; Maloney, A.; Sullivan, J.K.; Singh, S.; Millson, S.H.; Clarke, P.A.; Naaby-Hansen, S.; Stein, R.; Cramer, R.; Mollapour, M.; Workman, P.; Piper, P.W.; Pearl, L.H.; Prodromou, C. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone Aha1. Mol. Cell 2002, 10(6), 1307-1318.
85. McLaughlin, S.H.; Sobott, F.; Yao, Z.P.; Zhang, W.; Nielsen, P.R.; Grossmann, J.G.; Laue, E.D.; Robinson, C.V.; Jackson, S.E. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol. 2006, 356(3), 746-758.
86. Siligardi, G; Panaretou, B; Meyer, P.; Singh, S.; Woolfson, D.N.; Piper, P.W.; Pearl, L.H.; Prodromou, C. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J. Biol. Chem. 2002, 18, 754-762.
87. Roe, S.M.; Ali, M.M.; Meyer, P.; Vaughan, C.K.; Panaretou, B.; Piper, P.W.; Prodromou, C.; Pearl, L.H. The Mechanism of Hsp90 Regulation by the Protein Kinase-Specific Cochaperone p50(cdc37)/ Cell 2004, 116(1), 87-98.
88. Vaughan, C.K.; Mollapour, M.; Smith, J.R.; Truman, A.; Hu, B.; Good, V.M.; Panaretou, B.; Neckers, L.; Clarke, P.A.; Workman, P.; Piper, P.W.; Prodromou, C.; Pearl, L.H. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 2008, 31(6), 886-895.
89. Yang, J.; Roe, S.M.; Cliff, M.J.; Williams, M.A.; Ladbury, J.E.; Cohen, P.T.; Barford, D. Molecular basis for TPR domain-mediated regulation of protein phosphatase 5. EMBO. J. 2005, 24(1), 1-10.
90. Pearl, L.H. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 2005, 15(1), 55-61.
91. Smith, J.R.; Workman, P. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 2009, 8(3), 362-372.
92. Smith, J.R.; Clarke, P.A.; de Billy, E.; Workman, P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009, 28(2), 157-169.
93. Powers, M.V.; Clarke, P.A.; Workman, P. Death by chaperone: HSP90, HSP70 or both?. Cell Cycle 2009, 8(4), 518-526.
94. Silverstein, A.M.; Grammatikakis, N.; Cochran, B.H.; Chinkers, M; Pratt, W.B. P50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site. J. Biol. Chem. 1998, 273(32), 20090-20095.
95. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274(5292), 1531-1534.
96. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M.J.; Nettesheim, D.G.; Ng, S.; Nimmer, P.M.; O'Connor, J.M.; Oleksijew, A.; Petros, A.M.; Reed, J.C.; Shen, W.; Tahir, S.K.; Thompson, C.B.; Tomaselli, K.J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435(7042), 677-681.
97. Mandal, A.K.; Lee, P.; Chen, J.A.; Nillegoda, N.; Heller, A.; DiStasio, S.; Oen, H.; Victor, J.; Nair, D.M.; Brodsky, J.L.; Caplan, A.J. Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation. J. Cell. Biol. 2007, 176(3), 319-328.
98. Zhang, T; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C.G.; Sun, D.A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 2008, 7(1), 162-170.
99. Trott, A.; West, J.D.; Klaic, L.; Westerheide, S.D.; Silverman, R.B.; Morimoto, R.I.; Morano, K.A. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell 2008, 19(3), 1104-1112.
100. Sreeramulu, S; Gande, S.L.; Gobel, M.; Schwalbe, H. Molecular Mechanism of Inhibition of the Human Protein Complex Hsp90-Cdc37, a Kinome Chaperone-Cochaperone, by Triterpene Celastrol. Angew. Chem. Int. Ed Engl. 2009, 48(32), 1-4.
101. Das, A.K.; Cohen, P.T.W.; Barford, D. The structure of the tetratricopeptide repeats of protein phosphatase 5: implications for TPR-mediated protein-protein interactions. EMBO J. 1998, 17(5), 1192-1199.
102. Scheufler, C.; Brinker, A.; Bourenkov, G.; Pegoraro, S.; Moroder, L.; Bartunik, H.; Hartl, F. U.; Moarefi, I. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 2000, 101(2), 199-210.
103. Zhang, M.; Windheim, M.; Roe, S.M.; Peggie, M.; Cohen, P.; Prodromou, C.; Pearl, L.H. Chaperoned ubiquitylation - crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol. Cell 2005, 20(4), 525-538.
104. Taylor, P.; Dornan, J.; Carrello, A.; Minchin, R.F.; Ratajczak, T.; Walkinshaw, M.D. Two structures of cyclophilin 40: folding and fidelity in the TPR domains. Structure (Camb) 2001, 9(5), 431-438.
105. Sinars, C.R.; Cheung-Flynn, J.; Rimerman, R.A.; Scammell, J.G.; Smith, D.F.; Clardy, J. Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc. Natl. Acad. Sci. USA 2003, 100(3), 868-873.
106. Cliff, M.J.; Williams, M.A.; Brooke-Smith, J.; Barford, D.; Ladbury, J.E. Molecular recognition via coupled folding and binding in a TPR domain. J. Mol. Biol. 2005, 346(3), 717-732.
107. Ward, B.K.; Allan, R.K.; Mok, D.; Temple, S.E.; Taylor, P.; Dornan, J.; Mark, P.J.; Shaw, D.J.; Kumar, P.; Walkinshaw, M.D.; Ratajczak, T. A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90. J. Biol. Chem. 2002, 277(43), 40799-40809.
108. Cortajarena, A.L.; Yi, F.; Regan, L. Designed TPR modules as novel anticancer agents. ACS Chem. Biol. 2008, 3(3), 161-166.
109. Yi, F.; Regan, L. A novel class of small molecule inhibitors of Hsp90. ACS Chem. Biol. 2008, 3(10), 645-654.
110. Yi, F.; Zhu, P.; Southall, N.; Inglese, J.; Austin, C.P.; Zheng, W.; Regan, L. An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction. J. Biomol. Screen. 2009, 14(3), 273-281.
111. Prodromou, C; Siligardi, G; O'Brien, R; Woolfson, D.N.; Regan, L.; Panaretou, B.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J. 1999, 18(3), 754-762.
112. Richter, K.; Muschler, P.; Hainzl, O.; Reinstein, J.; Buchner, J. Sti1 is a noncompetitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the ATPase cycle. J. Biol. Chem. 2003, 278(12), 10328-10333.
113. Holmes, J.L.; Sharp, S.Y.; Hobbs, S.; Workman, P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Cancer Res. 2008, 68(4), 1188-1197.
114. Weaver, A.J.; Sullivan, W.P.; Felts, S.J.; Owen, B.A.; Toft, D.O. Crystal structure and activity of human p23, a heat shock protein 90 co- chaperone. J. Biol. Chem. 2000, 275(30), 23045-23052.
115. Panasenko, O.O.; Seit Nebi, A.; Bukach, O.V.; Marston, S.B.; Gusev, N.B. Structure and properties of avian small heat shock protein with molecular weight 25 kDa. Biochim. Biophys. Acta 2002, 1601(1), 64-74.
116. Van Montfort, R; Slingsby, C.; Vierling, E. Structure and function of the small heat shock protein/alpha-crystallin family of molecular chaperones. Adv. Protein Chem., 2001, 59, 105-156.
117. Grenert, J.P.; Johnson, B.D.; Toft, D.O. The importance of ATP binding and hydrolysis by Hsp90 in formation and function of protein heterocomplexes. J. Biol. Chem. 1999, 274(25), 17525-17533.
118. Zou, J., Guo, Y., Guettouche, T., Smith, D.F.; Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998, 94(4), 471-480.
119. Ali, A.; Bharadwaj, S.; O'Carroll, R.; Ovsenek, N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol. Cell Biol. 1998, 18(9), 4949-4960.
120. Guo, F; Rocha, K.; Bali, P.; Pranpat, M.; Fiskus, W.; Boyapalle, S.; Kumaraswamy, S.; Balasis, M.; Greedy, B.; Armitage, E.S.; Lawrence, N.; Bhalla, K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 2005, 65(22), 10536-10544.
121. McCollum, A.K.; Teneyck, C.J.; Sauer, B.M.; Toft, D.O.; Erlichman, C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 2006, 66(22), 10967-10975.
122. Voellmy, R.; Boellmann, F. Chaperone regulation of the heat shock protein response. Adv. Exp. Med. Biol. 2007, 594, 89-99.
123. Gabai, V.L.; Budagova, K.R.; Sherman, M.Y. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 2005, 24(20), 3328-3338.
124. Zaarur, N.; Gabai, V.L.; Porco, J.A.; Jr.; Calderwood, S.; Sherman, M.Y. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 2006, 66(3), 1783-1791.
125. Yaglom, J.A.; Gabai, V.L.; Sherman, M.Y. High levels of heat shock protein Hsp72 in cancer cells suppress default senescence pathways. Cancer Res. 2007, 67(5), 2373-2381.
126. Smith, D.F.; Whitesell, L.; Katsanis, E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev. 1998, 50(4), 493-514.
127. Lee, J.H.; Sun, D.; Cho, K.J.; Kim, M.S.; Hong, M.H.; Kim, I.K.; Lee, J.S.; Lee, J.H. Overexpression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay. J. Cancer Res. Clin. 2007, 133(1), 37-46.
128. Brodsky, J.L. Selectivity of the molecular chaperone-specific immunosuppressive agent 15-deoxyspergualin: modulation of Hsc70 ATPase activity without compromising DnaJ chaperone interactions. Biochem. Pharmacol. 1999, 57(8), 877-880.
129. Otaka, M.; Yamamoto, S.; Ogasawara, K.; Takaoka, Y.; Noguchi, S.; Miyazaki, T.; Nakai, A.; Odashima, M.; Matsuhashi, T.; Watanabe, S.; Itoh, H. The induction mechanism of the molecular chaperone HSP70 in the gastric mucosa by Geranylgeranylacetone (HSP-inducer). Biochem. Biophys. Res. Commun. 2007, 353(2), 399-404.
130. Liebscher, M; Jahreis, G.; Lucke, C.; Grabley, S.; Raina, S.; Schiene-Fischer, C. Fatty acyl benzamido antibacterials based on inhibition of DnaK-catalyzed protein folding. J. Biol. Chem. 2007, 282(7), 4437-4446.
131. Fewell, S.W.; Day, B.W.; Brodsky, J.L. Identification of an inhibitor of hsc70-mediated protein translocation and ATP hydrolysis. J. Biol. Chem. 2001, 276(2), 910-914.
132. Wisen, S; Androsavich, J; Evans, C.G.; Chang, L.; Gestwicki, J.E. Chemical modulators of heat shock protein 70 (Hsp70) by sequential, microwave-accelerated reactions on solid phase. Bioorg. Med. Chem. Lett. 2008, 18(1), 60-65.
133. Chakraborty, P.K.; Mustafi, S.B.; Ganguly, S.; Chatterjee, M.; Raha, S. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70. Cancer Sci. 2008, 99(6), 1109-1116.
134. Williamson, D.S.; Borgognoni, J.; Clay, A.; Daniels, Z.; Dokurno, P.; Drysdale, M.J.; Foloppe, N.; Francis, G.L.; Graham, C.J.; Howes, R.; Macias, A.T.; Murray, J.B.; Parsons, R.; Shaw, T.; Surgenor, A.E.; Terry, L.; Wang, Y.; Wood, M.; Massey, A. J. Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. J. Med. Chem. 2009, 52(6), 1510-1513.
135. Powers, M.V.; Clarke, P.A.; Workman, P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14(3), 250-262.
136. Plescia, J.; Salz, W.; Xia, F.; Pennati, M.; Zaffaroni, N.; Daidone, M.G.; Meli, M.; Dohi, T.; Fortugno, P.; Nefedova, Y.; Gabrilovich, D.I.; Colombo, G; Altieri, D.C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7(5), 457-468.
137. Gyurkocza, B.; Plescia, J.; Raskett, C.M.; Garlick, D.S.; Lowry, P.A.; Carter, B.Z.; Andreeff, M.; Meli, M.; Colombo, G.; Altieri, D.C. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl. Cancer Inst. 2006, 98(15), 1068-1077.
138. Meli, M.; Pennati, M.; Curto, M.; Daidone, M.G.; Plescia, J.; Toba, S.; Altieri, D.C.; Zaffaroni, N.; Colombo, G. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J. Med. Chem. 2006, 49(26), 7721-7730.